From viable spore to metabolic activity.
- 01
Ingest
Bacospore® viable spores in supplement, sachet or functional food.
- 02
Survive
Spores tolerate manufacturing, storage, gastric acid and bile.
- 03
Activate
Reach intestinal environment and become metabolically active.
- 04
Interact
Produce lactic acid, organic acids, enzymes, EPS and antimicrobial substances.
Spore survival & microbiota interaction
Bacospore® begins as a resilient spore designed to withstand processing, storage, and gastrointestinal conditions. Following exposure to favourable intestinal conditions, the strain can become metabolically active and interact with the surrounding microbial environment through multiple complementary mechanisms.
- Competitive interaction with other microorganisms
- Lactic acid production and local environmental acidification
- Production of bacteriocin-like antimicrobial substances
- Production of enzymes and metabolites associated with microbial activity
Mucosal defence & barrier support
Bacospore® has been investigated for effects relevant to gastrointestinal mucosal defence, including mucus integrity, epithelial barrier function, oxidative balance, and inflammatory signalling.
- Support for the gastric mucus barrier
- Maintenance of epithelial tight-junction integrity
- Modulation of oxidative stress
- Support for endogenous antioxidant systems
- Modulation of inflammatory mediators including TNF-α, IL-1β, and IL-6
Bile acid metabolism & cholesterol interaction
Probiotic-associated cholesterol reduction may involve several complementary mechanisms related to bile acid metabolism and microbial interaction with cholesterol.
- Bile salt deconjugation associated with BSH activity
- Incorporation or assimilation of cholesterol by microbial cells
- Interaction of cholesterol with deconjugated bile salts
- Potential changes in bile acid excretion
- Effects on pathways involved in cholesterol utilization
Designed for stability. Standardized for consistency.
For formulation development, the target inclusion level should be determined based on the required viable count at the end of shelf life, processing conditions, storage stability, and intended daily delivery.
The mechanisms described above are supported primarily by strain-specific in-vitro and animal studies. These findings provide a basis for further investigation but should not be interpreted as evidence of equivalent clinical effects in humans; additional mechanistic and clinical research is required to establish human outcomes.
